Can lamotrigine (Lamictal) cause a left bundle branch block?

Can Lamotrigine (Lamictal) Cause Left Bundle Branch Block?

Yes, lamotrigine can cause left bundle branch block (LBBB), particularly in overdose situations, though this is rare at therapeutic doses. The FDA drug label explicitly warns that lamotrigine exhibits Class IB antiarrhythmic activity and can slow ventricular conduction (widen QRS) and induce proarrhythmia in patients with underlying structural or functional heart disease 1.

Mechanism and Risk Profile

Lamotrigine blocks cardiac voltage-gated sodium channels at therapeutically relevant concentrations, which can affect the cardiac conduction system 1. This mechanism explains its potential to cause:

• QRS prolongation (widening of the QRS complex)
• Bundle branch blocks, including LBBB
• Proarrhythmias that could lead to sudden death in susceptible patients

Clinical Evidence

Overdose Situations

The clearest evidence comes from overdose cases:

• A case report documented transient LBBB following combined lamotrigine and citalopram overdose that was refractory to sodium bicarbonate therapy and eventually resolved spontaneously 2
• Another case described complete heart block and death following a 4-gram lamotrigine overdose 3
• These toxic LBBB cases appear to occur through mechanisms other than simple sodium channel blockade, as they don't respond to standard bicarbonate therapy 2

Therapeutic Doses

At therapeutic doses, the risk appears substantially lower:

• A large Danish population study of 91,949 lamotrigine users found no increased risk of cardiac conduction disorders in patients without pre-existing cardiac disease (adjusted HR 1.03,95% CI 0.76-1.40) 4
• Among 5,180 users with pre-existing cardiac disease, there was no increased all-cause mortality (adjusted HR 1.05,95% CI 0.93-1.19) 4

High-Risk Populations

The FDA specifically warns against using lamotrigine in patients with clinically important structural or functional heart disease, including 1:

• Heart failure
• Valvular heart disease
• Congenital heart disease
• Pre-existing conduction system disease
• Ventricular arrhythmias
• Cardiac channelopathies (e.g., Brugada syndrome)
• Clinically important ischemic heart disease
• Multiple risk factors for coronary artery disease

Clinical Recommendations

For patients requiring lamotrigine who have cardiac risk factors:

1. Carefully weigh benefits versus risks - Any expected benefit must be balanced against the risk of serious arrhythmias and/or death 1

2. Avoid concomitant sodium channel blockers - These may further increase proarrhythmia risk 1

3. Monitor for cardiac symptoms - Watch for syncope, palpitations, or other signs of conduction abnormalities

4. Consider baseline ECG - Particularly in patients with known or suspected cardiac disease

5. In overdose situations - Expect potential cardiac conduction abnormalities including LBBB, which may not respond to standard treatments like sodium bicarbonate 2

Important Caveats

While LBBB can occur with lamotrigine, it remains a rare adverse effect at therapeutic doses in patients without underlying cardiac disease 4. The primary cardiac concern with lamotrigine is in overdose situations or in patients with pre-existing structural heart disease where the drug's Class IB antiarrhythmic properties pose genuine risk 1.